ASND
Ascendis Pharma AS
NASDAQ: ASND · HEALTHCARE · BIOTECHNOLOGY
$220.28
-0.81% today
Updated 2026-04-29
Market cap
$13.61B
P/E ratio
—
P/S ratio
18.90x
EPS (TTM)
$-4.40
Dividend yield
—
52W range
$151 – $251
Volume
0.7M
Ascendis Pharma AS (ASND) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-31.70%
Operating margin
0.96%
ROE
-818.00%
ROA
-6.86%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $15.58M | $1.25M | 100.00% | 9.71% | 8.02% |
| 2013 | $20.41M | $4.08M | 100.00% | 25.87% | 19.99% |
| 2014 | $13.98M | $-9.66M | 100.00% | -85.74% | -69.07% |
| 2015 | $8.12M | $-32.92M | 100.00% | -515.21% | -405.54% |
| 2016 | $4.61M | $-68.50M | 100.00% | -1,583.15% | -1,487.30% |
| 2017 | $1.53M | $-123.90M | 100.00% | -7,290.26% | -8,097.84% |
| 2018 | $10.58M | $-130.10M | 100.00% | -1,462.59% | -1,229.53% |
| 2019 | $13.38M | $-218.02M | 100.00% | -1,695.10% | -1,630.03% |
| 2020 | $6.95M | $-418.95M | 100.00% | -4,755.07% | -6,025.53% |
| 2021 | $7.78M | $-383.58M | 54.71% | -5,808.59% | -4,931.56% |
| 2022 | $51.17M | $-583.19M | 76.28% | -1,097.85% | -1,139.63% |
| 2023 | $266.72M | $-481.45M | 83.36% | -170.79% | -180.51% |
| 2024 | $363.64M | $-378.08M | 87.83% | -76.66% | -103.97% |
| 2025 | $691.71M | $-219.03M | 85.08% | -18.92% | -31.67% |